CA2860690A1 - Diagnostic methods - Google Patents
Diagnostic methods Download PDFInfo
- Publication number
- CA2860690A1 CA2860690A1 CA2860690A CA2860690A CA2860690A1 CA 2860690 A1 CA2860690 A1 CA 2860690A1 CA 2860690 A CA2860690 A CA 2860690A CA 2860690 A CA2860690 A CA 2860690A CA 2860690 A1 CA2860690 A1 CA 2860690A1
- Authority
- CA
- Canada
- Prior art keywords
- assay
- array
- slide
- cells
- assay system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides a novel method that combines the features associated with a largely conventional FANA slide test and those of a largely conventional multiplex array assay into a single assay performed substantially simultaneously, with minimal modifications to each assay, to provide physicians and other users of the method with previously unknown advantages such as ease of use and enhanced assay speed that are useful, for example, for the diagnosis and assessment of autoimmune disorders.
Description
DIAGNOSTIC METHODS
Cross-Reference to Related Applications This application is a non-provisional application, which incorporates by reference herein and claims priority of US Provisional Application No. 61/429,892 and US
Provisional Application No. 61/524,630.
Background of the Invention Field of the Invention Generally, the present invention relates to the field of diagnostic assay systems, and in particular is useful for diagnosing and assessing autoimmune disorders, and more specifically the invention relates to novel methods for performing auto-antibody diagnostic assays.
Background Art Antibodies are proteins produced by the body in response to invading or infectious materials. They constitute one of the many means the body has to protect itself from 1 5 disease. In normal circumstances, the body can recognize "foreign" from "self' tissues, and therefore only generates antibodies to those materials that are "foreign" to the body.
Autoimmunity develops when the body begins to produce antibodies to its own tissues.
There are numerous types of autoimmune disorders; some systemic and others that are organ specific. The exact mechanism that initiates these diseases is not fully understood. Some may be easily treated with minimal patient impact while others can be quite severe and even fatal.
The symptoms associated with the onset of an autoimmune disorder can be varied. Also, any of the early symptoms can mimic those of many other diseases. Typically, if a patient visits a physician with symptoms remotely suggestive of an autoimmune disorder, the physician will usually suggest that an anti-nuclear antibody (ANA) test be performed. The At the present time, the most popular of the commercially available FANA tests is the so-20 Auto-antigens, used in the ANA test, represent the majority, but not all, of known auto-antigens expressed on the HEp-2 cell. Some auto-antigens found on the HEp-2 cell are not present in the multiplex suspension. Consequently, the multiplex bead method, such as the AtheNA Multi-Lyte ANA Test System (commercially available from Zeus Scientific, Inc., Bridgewater, NJ), contains a bead mix that is built on the Luminex xMAPO
platform (commercially available from Luminex Corporation, Austin, TX) using only a highly purified auto-antigen mixture conjugated onto separate microspheres and run as a multiplex assay. This system has most, but not all, of the auto-antigens found on the HEp-2 cell. For that reason, it would be desirable to include an actual HEp-2 cell along with the multiplex bead mix to ensure that the patient sample is tested for all potential autoantigens substantially simultaneously (all known and yet unknown autoantigens). However, while these types of sophisticated ANA tests are generally more specific than the traditional FANA
using HEp2 cells, they can be perceived to be under-sensitive, since they incorporate a limited and finite number of antigens. Collectively, these auto-antigens represent the majority of known auto-antigens expressed in the HEp-2 cell; however, the natural HEp2 cell theoretically supplies any and all auto-antigens that could likely exist in vivo.
While the HEp-2 FANA method has become the reference method, the aforementioned AtheNA Multi-Lyte ANA Test System provides substantially equivalent results, and there are those that feel that the ANA multiplex arrays are adequate and there are those that feel that only the HEp2 cell is sufficient in screening for ANA. However, it is generally agreed that following an acceptable screening method, providing the specific data from a multiplex array would be of extreme value.
Summary of the Invention In contrast to the conventional methodologies previously known, it is an object of the present invention to provide a novel method that combines the features associated with a largely conventional FANA slide test and those of a largely conventional multiplex array assay into a single assay performed substantially simultaneously, with minimal modifications to each assay, to provide physicians and other users of the method with previously unknown advantages such as ease of use and enhanced assay speed that are useful, for example, for the diagnosis and assessment of autoimmune disorders. The present invention additionally provides novel and unexpected advantages over the methods described and claimed in published International application No. PCT/1JS2009/056307, commonly assigned herewith and the disclosure of which is hereby incorporated by reference in its entirety. In contrast to the inventions disclosed and claimed in the above-referenced International application, the present invention has been found to achieve substantially similar goals and results without the necessity of using multiplex beads or instrumentation as described therein, by employing, 1 0 such as by printing, an array of antigen spots in proximity to cells that are fixed on a glass slide or other solid phase, and therefore the present invention is unexpectedly advantageous in that it does not require the involvement of multiplex bead arrays or instrumentation, such as the Luninex instrument referred to in said application.
Thus, it is an object of the invention to improve upon the technology disclosed in the art referenced above and upon the invention disclosed in the above-referenced PCT
application, by combining in a novel way the aforementioned conventional FANA
slide test and a multiplex array into a single assay, with minimal modifications to each.
So far as is known, it has not yet been attempted to combine these two very different immunoassays into a single immunoassay.
In accordance with the invention, these advantages are unexpectedly achieved from a combination of substantially simultaneous performance of these two types of immunoassays.
Cross-Reference to Related Applications This application is a non-provisional application, which incorporates by reference herein and claims priority of US Provisional Application No. 61/429,892 and US
Provisional Application No. 61/524,630.
Background of the Invention Field of the Invention Generally, the present invention relates to the field of diagnostic assay systems, and in particular is useful for diagnosing and assessing autoimmune disorders, and more specifically the invention relates to novel methods for performing auto-antibody diagnostic assays.
Background Art Antibodies are proteins produced by the body in response to invading or infectious materials. They constitute one of the many means the body has to protect itself from 1 5 disease. In normal circumstances, the body can recognize "foreign" from "self' tissues, and therefore only generates antibodies to those materials that are "foreign" to the body.
Autoimmunity develops when the body begins to produce antibodies to its own tissues.
There are numerous types of autoimmune disorders; some systemic and others that are organ specific. The exact mechanism that initiates these diseases is not fully understood. Some may be easily treated with minimal patient impact while others can be quite severe and even fatal.
The symptoms associated with the onset of an autoimmune disorder can be varied. Also, any of the early symptoms can mimic those of many other diseases. Typically, if a patient visits a physician with symptoms remotely suggestive of an autoimmune disorder, the physician will usually suggest that an anti-nuclear antibody (ANA) test be performed. The At the present time, the most popular of the commercially available FANA tests is the so-20 Auto-antigens, used in the ANA test, represent the majority, but not all, of known auto-antigens expressed on the HEp-2 cell. Some auto-antigens found on the HEp-2 cell are not present in the multiplex suspension. Consequently, the multiplex bead method, such as the AtheNA Multi-Lyte ANA Test System (commercially available from Zeus Scientific, Inc., Bridgewater, NJ), contains a bead mix that is built on the Luminex xMAPO
platform (commercially available from Luminex Corporation, Austin, TX) using only a highly purified auto-antigen mixture conjugated onto separate microspheres and run as a multiplex assay. This system has most, but not all, of the auto-antigens found on the HEp-2 cell. For that reason, it would be desirable to include an actual HEp-2 cell along with the multiplex bead mix to ensure that the patient sample is tested for all potential autoantigens substantially simultaneously (all known and yet unknown autoantigens). However, while these types of sophisticated ANA tests are generally more specific than the traditional FANA
using HEp2 cells, they can be perceived to be under-sensitive, since they incorporate a limited and finite number of antigens. Collectively, these auto-antigens represent the majority of known auto-antigens expressed in the HEp-2 cell; however, the natural HEp2 cell theoretically supplies any and all auto-antigens that could likely exist in vivo.
While the HEp-2 FANA method has become the reference method, the aforementioned AtheNA Multi-Lyte ANA Test System provides substantially equivalent results, and there are those that feel that the ANA multiplex arrays are adequate and there are those that feel that only the HEp2 cell is sufficient in screening for ANA. However, it is generally agreed that following an acceptable screening method, providing the specific data from a multiplex array would be of extreme value.
Summary of the Invention In contrast to the conventional methodologies previously known, it is an object of the present invention to provide a novel method that combines the features associated with a largely conventional FANA slide test and those of a largely conventional multiplex array assay into a single assay performed substantially simultaneously, with minimal modifications to each assay, to provide physicians and other users of the method with previously unknown advantages such as ease of use and enhanced assay speed that are useful, for example, for the diagnosis and assessment of autoimmune disorders. The present invention additionally provides novel and unexpected advantages over the methods described and claimed in published International application No. PCT/1JS2009/056307, commonly assigned herewith and the disclosure of which is hereby incorporated by reference in its entirety. In contrast to the inventions disclosed and claimed in the above-referenced International application, the present invention has been found to achieve substantially similar goals and results without the necessity of using multiplex beads or instrumentation as described therein, by employing, 1 0 such as by printing, an array of antigen spots in proximity to cells that are fixed on a glass slide or other solid phase, and therefore the present invention is unexpectedly advantageous in that it does not require the involvement of multiplex bead arrays or instrumentation, such as the Luninex instrument referred to in said application.
Thus, it is an object of the invention to improve upon the technology disclosed in the art referenced above and upon the invention disclosed in the above-referenced PCT
application, by combining in a novel way the aforementioned conventional FANA
slide test and a multiplex array into a single assay, with minimal modifications to each.
So far as is known, it has not yet been attempted to combine these two very different immunoassays into a single immunoassay.
In accordance with the invention, these advantages are unexpectedly achieved from a combination of substantially simultaneous performance of these two types of immunoassays.
Brief Description of the Drawings Figure 1 shows examples of positive ANA reactions; specific patterns of reactivity are shown using HEp-2 FANA (performed using a conventional slide method).
Figure 2 shows a dual-spotted slide array for cells utilizing the methods of the present invention.
Figure 3 shows a slide and flexible grid used to form wells for performing the methods of the present invention.
Figure 4 shows a formation of wells on a slide useful for performing the methods of the invention, so that each well contains two areas; one with cells and one with a defined antigen array.
Detailed Description of the Invention As discussed above, the symptoms associated with the onset of an autoimmune disorder can be quite varied. Also, any of the early symptoms can mimic those of many other diseases. The ANA screening test is widely recognized as a good "first round"
1 5 screening test to see if a patient has antibody to self tissues, the currently most popular being the fluorescent anti-nuclear antibody assay (FANA), and the currently most popular of the FANA tests being the HEp-2 FANA. The assay is performed by allowing the patient serum to react to the cells. If anti-nuclear antibodies are present, they will bind to the cells. The patient antibody is then tagged with anti-human Ig labeled with a fluorescent moiety. When viewed using a properly equipped microscope, specific patterns of reactivity are observed (if present) and some have been highly associated with specific autoimmune disorders.
Examples of some positive reactions appear in Figure 1 of the drawings.
Figure 2 shows a dual-spotted slide array for cells utilizing the methods of the present invention.
Figure 3 shows a slide and flexible grid used to form wells for performing the methods of the present invention.
Figure 4 shows a formation of wells on a slide useful for performing the methods of the invention, so that each well contains two areas; one with cells and one with a defined antigen array.
Detailed Description of the Invention As discussed above, the symptoms associated with the onset of an autoimmune disorder can be quite varied. Also, any of the early symptoms can mimic those of many other diseases. The ANA screening test is widely recognized as a good "first round"
1 5 screening test to see if a patient has antibody to self tissues, the currently most popular being the fluorescent anti-nuclear antibody assay (FANA), and the currently most popular of the FANA tests being the HEp-2 FANA. The assay is performed by allowing the patient serum to react to the cells. If anti-nuclear antibodies are present, they will bind to the cells. The patient antibody is then tagged with anti-human Ig labeled with a fluorescent moiety. When viewed using a properly equipped microscope, specific patterns of reactivity are observed (if present) and some have been highly associated with specific autoimmune disorders.
Examples of some positive reactions appear in Figure 1 of the drawings.
Accordingly, the present invention, in preferred embodiments, provides novel methods for the substantially simultaneous analysis of autoantigens in a single sample from a subject by combining the known FANA slide tests and multiplex arrays into a single assay, with minimal modifications to each. The HEp-2 FANA test comprises a slide test using HEp-2 cells that have been allowed to grow in TC media on the surface of glass slides. The slides are then rinsed and the cells fixed with conventional organic solvents, thus permeabalizing the membrane and keeping the cells adhered to the glass slides.
This assay can be performed, for example, in the small wells of a microscope slide.
Definitions:
1. Multiplex Array Platform: as used herein, a multiplex array platform is any platform that enables one to test for multiple analytes simultaneously. Common array systems involve spotting target molecules in precise locations on a solid support such as glass or plastic. A popular example of a widely used multiplex array platform is the system developed and commercially available based on the Luminex@ xMAP@ Technology (Luminex Corporation, Austin, TX). Other arrays are known to be fabricated with spots, wells, posts, beads, cantilevers, wires, electrodes or fiber optics (see Clinical Chemistry;
56:12 (2010)).
2. Reporter Molecule: as used herein means the reporter molecule is the fluorescent, visual or chemiluminescent tag that is bound to the detection molecule(s) in the assay. In the case of immunoassays designed to measure human antibody, the detection molecule may be goat anti-human IgG (for example) that is labeled with phycoerythrin (for example).
This assay can be performed, for example, in the small wells of a microscope slide.
Definitions:
1. Multiplex Array Platform: as used herein, a multiplex array platform is any platform that enables one to test for multiple analytes simultaneously. Common array systems involve spotting target molecules in precise locations on a solid support such as glass or plastic. A popular example of a widely used multiplex array platform is the system developed and commercially available based on the Luminex@ xMAP@ Technology (Luminex Corporation, Austin, TX). Other arrays are known to be fabricated with spots, wells, posts, beads, cantilevers, wires, electrodes or fiber optics (see Clinical Chemistry;
56:12 (2010)).
2. Reporter Molecule: as used herein means the reporter molecule is the fluorescent, visual or chemiluminescent tag that is bound to the detection molecule(s) in the assay. In the case of immunoassays designed to measure human antibody, the detection molecule may be goat anti-human IgG (for example) that is labeled with phycoerythrin (for example).
3. Cellular substrate: as used herein means any cellular material or tissue substrate that is generally adhered to a solid support (glass or plastic microscope slide) and then used as part of a biochemical assay for analysis of biomolecules such as antibody or antigens.
The combination assay as provided by the present invention therefore can be performed without the use of, instrumention such as for example, a conventional Luminex xMAP instrument, which is essentially a flow cytometer that has been modified for use of the Luminex polystyrene microspheres in a multiplex bead assay. The present invention is therefore greatly advantageous over know methods in the art for performing similar assays, in the aspect of simplicity and lack of need for expensive instrumentation, among other 1 0 advantages which will be apparent to those skilled in the art.
In a preferred embodiment, the array in the case of the present invention comprises a series of purified antigens that have been spotted onto a glass slide in proximity to the cellular substrate containing cells that are of interest to analyze. The array can be as simple or as complex as desired, depending on the nature of the assay in question.
For the ANA
example, it is presently preferred that a minimum of 10 highly purified auto-antigens, and preferably a maximum of 20 to 25 highly purified auto-antigens, be used.
For example, the practice of the methods of the present invention typically begins with a glass slide. Preferably, a glass slide with two "areas" per "well" (see Figure 2 of the drawings) is used. The cells of interest are en applied, thereby creating a cellular substrate and fixed into the circular wells in the image shown in Figure 2. Then, the purified antigens are spotted in proximity to the substrate as an array in the square wells shown in Figure 2.
This slide is thereafter packaged and provided to the user of the assay system, for further analysis of patient specimens in accordance with the user's needs. For analysis, the slide may be modified as needed by the user so that wells are formed for each patient specimen.
The wells can be configured, for example, so that each well contains one circle (HEp2 cells) and one square (purified antigen array). Figures 3 and 4 of the drawings depict the formation of these wells. This slide can then be used to evaluate patient specimens (for example, serum, urine, plasma, etc.) for reactivity to the combination of the cells and the antigen array, substantially all simultaneously, using suitable reporter molecules well known to those skilled in the art, and thereby providing a novel way to collect the combination of reactivity to naturally occurring biomolecules within fixed cells or tissues, as well as an array of highly specific, highly purified biomolecules.
In a preferred embodiment of the present invention, the HEp-2 FANA test comprises a slide test using HEp-2 cells that have been allowed to grow in TC media on the surface of the glass slide. They are rinsed and fixed with some organic solvents, which permeabalizes the membrane and keeps them adhered to the glass slide. This assay has conventionally been performed in tiny wells of a microscope slide. However, the array (in this case 1 5 according to the invention) is a series of purified antigens that have been spotted onto a glass slide for reactivity to the combination of the cells and the antigen array all substantially simultaneously.
It is to be appreciated that in addition, while the above example focuses on measuring autoantibodies in patients with possible autoimmune disorders, the present invention could be applied to a myriad of other examples including autoimmune, infectious disease, cancer diagnostics, cytological studies, to name only a few. Other examples will be apparent to those skilled in the art.
The combination assay as provided by the present invention therefore can be performed without the use of, instrumention such as for example, a conventional Luminex xMAP instrument, which is essentially a flow cytometer that has been modified for use of the Luminex polystyrene microspheres in a multiplex bead assay. The present invention is therefore greatly advantageous over know methods in the art for performing similar assays, in the aspect of simplicity and lack of need for expensive instrumentation, among other 1 0 advantages which will be apparent to those skilled in the art.
In a preferred embodiment, the array in the case of the present invention comprises a series of purified antigens that have been spotted onto a glass slide in proximity to the cellular substrate containing cells that are of interest to analyze. The array can be as simple or as complex as desired, depending on the nature of the assay in question.
For the ANA
example, it is presently preferred that a minimum of 10 highly purified auto-antigens, and preferably a maximum of 20 to 25 highly purified auto-antigens, be used.
For example, the practice of the methods of the present invention typically begins with a glass slide. Preferably, a glass slide with two "areas" per "well" (see Figure 2 of the drawings) is used. The cells of interest are en applied, thereby creating a cellular substrate and fixed into the circular wells in the image shown in Figure 2. Then, the purified antigens are spotted in proximity to the substrate as an array in the square wells shown in Figure 2.
This slide is thereafter packaged and provided to the user of the assay system, for further analysis of patient specimens in accordance with the user's needs. For analysis, the slide may be modified as needed by the user so that wells are formed for each patient specimen.
The wells can be configured, for example, so that each well contains one circle (HEp2 cells) and one square (purified antigen array). Figures 3 and 4 of the drawings depict the formation of these wells. This slide can then be used to evaluate patient specimens (for example, serum, urine, plasma, etc.) for reactivity to the combination of the cells and the antigen array, substantially all simultaneously, using suitable reporter molecules well known to those skilled in the art, and thereby providing a novel way to collect the combination of reactivity to naturally occurring biomolecules within fixed cells or tissues, as well as an array of highly specific, highly purified biomolecules.
In a preferred embodiment of the present invention, the HEp-2 FANA test comprises a slide test using HEp-2 cells that have been allowed to grow in TC media on the surface of the glass slide. They are rinsed and fixed with some organic solvents, which permeabalizes the membrane and keeps them adhered to the glass slide. This assay has conventionally been performed in tiny wells of a microscope slide. However, the array (in this case 1 5 according to the invention) is a series of purified antigens that have been spotted onto a glass slide for reactivity to the combination of the cells and the antigen array all substantially simultaneously.
It is to be appreciated that in addition, while the above example focuses on measuring autoantibodies in patients with possible autoimmune disorders, the present invention could be applied to a myriad of other examples including autoimmune, infectious disease, cancer diagnostics, cytological studies, to name only a few. Other examples will be apparent to those skilled in the art.
It will also be appreciated that in addition to analysis of serum samples as described above, the methods and teachings of the present invention can be applied to analysis of any biological fluid that may be obtained from a subject; for example, blood, urine, cerebral spinal fluid and plasma, as well as other biological fluids as are well known to those skilled in the art, can all be suitable for obtaining samples upon which to perform the methods of analysis in accordance with the present invention.
Further, it is to be appreciated that many additional modifications and variations, that will be apparent to and appreciated by those skilled in the art in view of the disclosure herein, may be made in the specific embodiments of the invention as described herein, and that all such modifications are fully within the scope of the present invention, which is intended to be limited only by the claims appended hereto.
Further, it is to be appreciated that many additional modifications and variations, that will be apparent to and appreciated by those skilled in the art in view of the disclosure herein, may be made in the specific embodiments of the invention as described herein, and that all such modifications are fully within the scope of the present invention, which is intended to be limited only by the claims appended hereto.
Claims (10)
1. A method for performing diagnostic assays on a biological sample, which method comprises combining a FANA slide test assay and a multiplex array assay to produce a single assay system.
2. The method of claim 1, wherein the assays comprise auto-antibody immunoassays.
3. The method of claim 1, wherein the assays comprise an array of antigen spots in proximity to cells that are fixed on a glass slide or other solid phase.
4. The method of claim 1, wherein the antigen spots are applied by printing.
5. The method of claim 1, wherein the assays are performed substantially simultaneously.
6. The method of claim 1, wherein the assay system comprises a slide and flexible grid used to form wells.
7. The method of claim 6, wherein the wells each contain two areas, one with cells and one with a defined antigen array.
8. The method of claim 1, wherein at least 10 highly purified auto-antigens are used in the assay system.
9. The method of claim 1, wherein the assay system is useful for the diagnosis and assessment of conditions selected from the group consisting of autoimmune disorders, infectious disease or cancer diagnostics, or for cytological studies.
10. The method of claim 1, wherein the sample is selected from the group consisting of serum, blood, urine, cerebral spinal fluid or plasma, as well as other biological fluids.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161429892P | 2011-01-05 | 2011-01-05 | |
| US61/429,892 | 2011-01-05 | ||
| US201161524630P | 2011-08-17 | 2011-08-17 | |
| US61/524,630 | 2011-08-17 | ||
| PCT/US2012/020234 WO2012094427A1 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2860690A1 true CA2860690A1 (en) | 2012-07-12 |
Family
ID=46457702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2860690A Abandoned CA2860690A1 (en) | 2011-01-05 | 2012-01-04 | Diagnostic methods |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2661625A4 (en) |
| JP (1) | JP2014501932A (en) |
| CN (1) | CN103460043A (en) |
| AU (1) | AU2012204413A1 (en) |
| CA (1) | CA2860690A1 (en) |
| WO (1) | WO2012094427A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3591406A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Device and method for antibody detection |
| EP3591401A1 (en) | 2018-07-06 | 2020-01-08 | Euroimmun Medizinische Labordiagnostika AG | Method for the automated detection of antibodies in a liquid biological sample using an antigen chip |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60183559A (en) * | 1984-02-29 | 1985-09-19 | Otsuka Pharmaceut Co Ltd | Method for measuring autoantibody for hepato-cellular membrane antigen |
| US5518881A (en) * | 1993-11-02 | 1996-05-21 | Flinders Medical Centre | Transfected cell lines expressing autoantigens and their use in immunoassays for the detection of autoimmune disease |
| EP0852004B1 (en) * | 1995-10-11 | 2011-01-19 | Luminex Corporation | Multiplexed analysis of clinical specimens |
| CN1101936C (en) * | 2000-08-14 | 2003-02-19 | 李永哲 | Preparation method of antinuclear antibody detection reagent Hep-2 cell antigen fragment and its product |
| US7189516B2 (en) * | 2001-08-17 | 2007-03-13 | Luminex Corporation | Method for characterizing autoimmune disorders |
| US20030104439A1 (en) * | 2001-11-30 | 2003-06-05 | Finch Rosalynde J. | Methods of identifying cellular target molecules |
| CN2653510Y (en) * | 2003-09-25 | 2004-11-03 | 长沙福滋堂生物技术开发有限公司 | Anti-nuclear antigen detection cell thin sheet |
| EP2089712A4 (en) * | 2006-11-22 | 2010-09-22 | Life Technologies Corp | Autoimmune disease biomarkers |
| CN101017168B (en) * | 2007-02-15 | 2012-08-29 | 广州万孚生物技术股份有限公司 | Fluorescence rubber latex quantitative chromatography indicator paper and manufacture method thereof |
| DE102007052281A1 (en) * | 2007-11-02 | 2009-05-07 | Zenteris Gmbh | Single-step multiplex immunoassay |
| EP2208068B1 (en) * | 2007-11-13 | 2013-04-17 | Medipan GmbH | Method for end-titre determination and the evaluation thereof by means of an indirect immunofluorescence assay |
| WO2010030624A1 (en) * | 2008-09-09 | 2010-03-18 | Zeus Scientific, Inc. | Methods for diagnosis and assessment of autoimmune disorders |
| US8630690B2 (en) * | 2009-05-05 | 2014-01-14 | Electric Power Research Institute, Inc. | Thermal contraction compensation for superconducting and cryo-resistive cables |
| EP2362222B1 (en) * | 2010-02-22 | 2013-06-26 | Medipan GmbH | Method and device for the simultaneous detection of antibodies bound to synthetic and cellular and/or tissue substrates |
-
2012
- 2012-01-04 CA CA2860690A patent/CA2860690A1/en not_active Abandoned
- 2012-01-04 EP EP12732021.6A patent/EP2661625A4/en not_active Withdrawn
- 2012-01-04 CN CN201280005699XA patent/CN103460043A/en active Pending
- 2012-01-04 WO PCT/US2012/020234 patent/WO2012094427A1/en active Application Filing
- 2012-01-04 JP JP2013548490A patent/JP2014501932A/en active Pending
- 2012-01-04 AU AU2012204413A patent/AU2012204413A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014501932A (en) | 2014-01-23 |
| WO2012094427A1 (en) | 2012-07-12 |
| CN103460043A (en) | 2013-12-18 |
| EP2661625A1 (en) | 2013-11-13 |
| EP2661625A4 (en) | 2014-10-29 |
| AU2012204413A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hartmann et al. | Protein microarrays for diagnostic assays | |
| EP1322960B1 (en) | Allergen-microarray assay | |
| US20080058224A1 (en) | Substrate chemistry for protein immobilization on a rigid support | |
| AU2002212306A1 (en) | Allergen-microarray assay | |
| JP2013520664A (en) | Method and system for disease diagnosis by simultaneous detection of antibodies bound to synthetic and cell substrates | |
| JP2010500537A (en) | Improved immunoassay containing mutant antigens to reduce non-specific binding | |
| CA2860690A1 (en) | Diagnostic methods | |
| CA2698437A1 (en) | Marker sequences for rheumatoid arthritis and use thereof | |
| Bacarese-Hamilton et al. | Allergen microarrays | |
| ES2791981T3 (en) | Antibody detection method and system | |
| Sauer et al. | Critical role of the sample matrix in a point-of-care protein chip for sepsis | |
| KR102172016B1 (en) | A method for detection of CYFRA21-1 Autoantibody-Antigen complex , CYFRA21-1 antigen and Lung Cancer diagnosis kit by using ratio of these markers | |
| US20120040850A1 (en) | Methods for Diagnosis and Assessment of Autoimmune Disorders | |
| US20130217015A1 (en) | Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer | |
| CA2939789C (en) | Red blood cell detection | |
| KR20140067104A (en) | Calibration reagent and method | |
| Sohn et al. | ANA testing | |
| LU100002B1 (en) | New testing device and method for detecting Ankylosing Spondylitis | |
| Saxena et al. | Immunotechnology in Disease Diagnosis | |
| EP3283888B1 (en) | A method for in vitro diagnosis of allergy and related device | |
| JP2024030655A (en) | Reagent and method for testing for lymphocytic anterior hypophysitis and isolated adrenocorticotropic hormone deficiency | |
| CN109725157A (en) | Application of the polypeptide SLE2018-V003 in diagnostic system lupus erythematosus kit | |
| CN109725155A (en) | Application of the polypeptide SLE2018-V004 in diagnostic system lupus erythematosus kit | |
| EP2171473A2 (en) | A novel diagnostic sensor for rapid and reproducible ro52 protein domain detection | |
| US20110236912A1 (en) | Systems and methods for characterizing lupus erythematosus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20170104 |